tbuckley/cabot-search huggingface dataset:
P12.07 * EPIDERMOID AND DERMOID CYSTS OF THE CENTRAL NERVOUS SYSTEM: SURGICAL RESULTS
Authors: T. S. Havryliv, V. Smolanka
Journal: Neuro-Oncology (2014)

INTRODUCTION: Epidermoid and dermoid cysts of the central nervous system are usually developmental, benign tumors that arise when retained ectodermal implants are trapped by two fusing ectodermal surfaces. Together they compromise 1 - 1.5% of all brain tumors. Epidermoid cysts consist solely of layers of stratified squamous epithelium and localize more laterally (lateral sulcus, cerebellopontine angle (CP-angle)). Dermoid cysts also include dermal appendage organs (hair follicles and sebaceous glands). Unlike epidermoids, they are placed in the midline (suprasellary, IV ventricle). The aim of the current study was to define the clinical course and results of surgical treatment of dermoid and epidermoid cysts, depending on their location and tumor type. MATERIALS AND METHODS: A retrospective analysis of 16 consecutive surgical interventions on brain epidermoids and dermoids (4 dermoid cyst, 12 - epidermoid cysts), that were treated at the Uzhhorod Regional Clinical Center of Neurosurgery and Neurology in the period from January 2009 to February 2013. The distribution of patients by gender and age: men - 9, women - 7; mean age of patients - 30.1 years. Localization of the tumours was as follows: epidermoids (cerebellopontine angle - 6 patients, lateral sulcus - 4 patients, parietal lobe and spinal cord - 1 patient each); dermoid cysts (suprasellary - 3 patients, IV ventricle - 1 patient). RESULTS AND DISCUSSION: In the clinical picture of 7 patients the dominant symptom was focal neurological deficit (paresis of the extremities, dysfunction of cranial nerves), 6 patients presented with seizures and 3 patients with occlusive hydrocephalic syndrome. Hydrocephalic-occlusive syndrome dominated the clinical picture in 2 patients with CP-angle epidermoid and in patients with dermoid cyst of the IV ventricle. 13 patients underwent total removal of dermoid and epidermoid cysts, which was confirmed by control MRI, in 3 - a small part of the tumor capsule, closely linked with one of the large vessels of the brain (middle cerebral artery, basilar artery, posterior cerebral artery), was left. 14 of 16 patients (88%) noted improvement immediately after surgery. In 1 patient with epidermoid cyst of CP-angle there was new neurological deficit after surgery, that totally resolved after ventriculoperitoneal shunting. The median follow-up of the study was 3.1 years. The results of the treatment were assessed according to Karnofsky scale: more then 60 points - 16 patients. CONCLUSIONS: The only effective treatment for epidermoid and dermoid tumors is surgical removal. Careful microsurgical removal of these tumors can achieve satisfactory results and long-term remission. There is no influence of tumor localization on surgical results of the treatment.
Sabarubicin (SABA) in combination with cisplatin (DDP): Maximum tolerated dose (MTD) evaluation (phase I step) followed by a phase II step in patients (pts) with small cell lung cancer-extensive disease (SCLC-ED).
Authors: O. A. Cornely, J. Wolf, K. M. Josten, T. Mueller, H. A. Duerk, W. Neumeister, M. Sebastian, C. Simonelli, A. Capriati, M. Karthaus
Journal: Journal of Clinical Oncology (2010)

7048 Background: SABA, a 3rd generation anthracycline with promising activity as single agent in solid tumors was evaluated to establish the MTD in combination with DDP (phase I), followed by a phase II evaluating SABA + DDP as first line therapy in SCLC-ED pts. Methods: In phase I, MTD was evaluated with ascending SABA doses of 40, 60, 80 and then 10 mg/m2 increments (day 1) together with a fixed dose of DDP 80 mg/m2 (day 2) in pts with solid tumors. In phase II, SABA 80 mg/m2 and DDP 80 mg/m2 iv q21 days for 6 cycles were primarily assessed for complete or partial response (CR/PR); secondarily for overall survival (OS), duration of tumor response (DTR), time to progression (TTP), and safety in chemotherapy-naive SCLC-ED pts. Results: Phase I recruited 17 pts. Best response was PR in 3 (23.1%) pts. Dose-limiting toxicity occurred in 2 of 5 pts at SABA 90 mg/m2, i.e. grade (G) 4 thrombocytopenia and G 4 neutropenia associated with G 3 pyrexia. MTD for phase II was 80 mg/m2. In phase II 17 males, 8 females with SCLC-ED (mean age 63 years) were enrolled. One (4%) pt was excluded from the efficacy population for a delay of study therapy for non-medical reasons. Nineteen (79.2%) pts achieved CR (1; 4.2%) or PR (18; 75%), 4 (16.7%) SD, and 1 (4.2%) progressed. Median OS, DTR and TTP were 11.6, 3.8 and 6.5 months, respectively. In phase II treatment-related AEs referred mainly to the gastrointestinal (69 AEs in 21 (84%) pts) or hematological system (84 AEs in 19 (76%) pts). Premature study discontinuation occurred in 7 (28%) pts due to 8 AEs. In 13 (52%) pts 20 G 4 related AEs were reported, 18 of 20 were blood/lymphatic system. In total, 2 cardiac SAEs occurred: 1/42 (2.4%) G 2 heart failure and 1 G 2 (2.4%) tachycardia. No clinically significant signals were detected in laboratory and physical evaluation, ECG and echocardiography. Fatal AEs with a suspected relationship to SABA + DDP occurred at the lowest SABA dose (40 mg/m2) in phase I and in phase II (80 mg/m2) in one pt each. Conclusions: SABA in combination with 80 mg/m2 DDP reached MTD at 80 mg/m2. SABA + DDP were effective and safe as first line treatment in SCLC-ED, which appears comparable to standard regimens. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Menarini Ricerche
Predictive value of p27 for the benefit of adjuvant anthracycline-based chemotherapy in early breast cancer.
Authors: R Conforti, CB Moeder, G Tomasic, T Boulet, R Nahta, LX Yuan, M Spielmann, S Delaloge, S Michiels, DL Rimm, FJ Esteva, F Andre
Journal: Cancer Research (2009)

Abstract Abstract #6063 Background: p27 is a cyclin-dependent kinase (cdk) inhibitor that plays a role in cell cycle regulation. The expression of this protein, assessed by immunohistochemistry (IHC), has prognostic value for overall survival in breast cancer patients (Porter P.L., J Natl Cancer Inst., 2007). Based on this, we hypothesized that p27 could be a predictive factor for the efficacy of adjuvant anthracycline (A)-based chemotherapy in early breast cancer.&amp;#x2028; Methods: Tumor samples from 823 patients, included at Institut Gustave Roussy (IGR) in two randomized trials comparing an A-based chemotherapy with no adjuvant treatment, were used to construct a tissue microarray. We previously reported predictive values of ER, Her2 expression and molecular subclassification using the same tissue array (Conforti R., Ann Oncol., 2007). Nuclear and cytoplasmic expression of p27 was assessed by the AQUA system. A p27 ratio of nuclear and cytoplasmic expression (p27 N/C ratio) was calculated for each tumor sample. The prognostic and predictive value of the continuous value of p27 N/C ratio was assessed by a Cox regression model adjusted for treatment, age, tumor grade, stage and ER expression (IHC) and stratified by trial.&amp;#x2028; Results: p27 was assessable in 715 primary tumors. The p27 N/C ratio was significantly different according to the molecular subclasses (p=0.001) and was higher in Her2- versus Her2+ and in EGFR+ versus EGFR- tumors (p=0.0075 and p&amp;lt;0.0001 respectively). There was an almost significant interaction between p27 N/C ratio and disease-free survival in the adjusted Cox model (p=0.052). The adjusted hazard ratios (HR) of relapse or death of a unit increase in p27 N/C ratio was HR = 1.27 (95% CI = [0.58-2.81], p = 0.55) in the control arm and HR = 0.30 (95% CI = [0.12-0.77], p= 0.01) in the A-arm. For overall survival, the adjusted interaction p-value was equal to 0.08. The adjusted HR of death of a unit increase in p27 N/C ratio was HR=1.67 (95% CI = [0.61-1.73], p=0.32) in the control arm and HR=0.32 (95% CI = [0.10-0.99], p=0.05) in the A-arm.&amp;#x2028; Conclusion: p27 N/C ratio, determined by the AQUA system, was borderline predictive for the efficacy of adjuvant A-based chemotherapy. However, this study is hampered by a relatively low number of events, a low dose of anthracycline, and multi-hypotheses testing (overall 20 biomarkers tested in different studies). Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 6063.
Poly(A) Polymerase Activity in Murine Serum. Elevation in Animals With Proliferative Changes
Authors: R. N. Kurl, S. C. Holmes, E. Verney, H. Sidransky
Journal: JNCI Journal of the National Cancer Institute (1988)

Journal Article Poly(A) Polymerase Activity in Murine Serum. Elevation in Animals With Proliferative Changes Get access Rabinder N. Kurl, Rabinder N. Kurl Search for other works by this author on: Oxford Academic PubMed Google Scholar Stephanie C. Holmes, Stephanie C. Holmes Search for other works by this author on: Oxford Academic PubMed Google Scholar Ethel Verney, Ethel Verney Search for other works by this author on: Oxford Academic PubMed Google Scholar Herschel Sidransky Herschel Sidransky * 3Department of Pathology, George Washington University Medical CenterWashington, DC. Correspondence to: Dr. Herschel Sidransky, Department of Pathology, George Washington University Medical Center, 2300 Eye St, N.W., Washington, DC 20037. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 80, Issue 13, 7 September 1988, Pages 1060–1065, https://doi.org/10.1093/jnci/80.13.1060 Published: 07 September 1988 Article history Received: 06 April 1988 Revision received: 16 May 1988 Accepted: 20 May 1988 Published: 07 September 1988
TICAGRELOR POTENTIATES NEUTROPHIL PHAGOCYTOSIS VIA INHIBITION OF ADENOSINE REUPTAKE BY ERYTHROCYTES
Authors: Mark R. Thomas, Khalaf F. Alsharif, Lynne R. Prince, Victoria C. Ridger, Heather M. Judge, David H. Dockrell, Ian Sabroe, Robert F. Storey
Journal: Journal of the American College of Cardiology (2015)
Acute Infectious Lymphocytosis in Young Adults
Authors: Peter A. Duncan
Journal: New England Journal of Medicine (1945)

ACUTE infectious lymphocytosis, a clinical entity featured by a benign relative and absolute increase in the number of small mature lymphocytes, was first described in 1941 by Smith.1 He presented 2 cases of this disease and expressed the opinion that the group of patients reported by Reyersbach and Lenert2 and 1 case described by Wilson and Cunningham3 belonged in this classification rather than among the cases of infectious mononucleosis, as reported. There were no significant clinical signs or symptoms in any of these cases. Another case of acute infectious lymphocytosis presenting a marked symptomatology has been described,4 and the belief . . .
Abstract LB-96: Id1 enhances RING1b E3 ubiquitin ligase activity through the Mel-18/Bmi-1 polycomb group complex
Authors: Tingting Qian, Jeong-Yeon Lee, Hyun-Jun Kim, Gu Kong
Journal: Cancer Research (2010)

Abstract The helix-loop-helix inhibitor of differentiation and DNA binding (Id1) is well-known as an oncogene in various tumors. Although it has been reported that Id-1 promotes several oncogenic processes, it is still unclear whether Id1 functions through epigenetic transcriptional regulation. In this study, we examined the effect of Id1 on polycomb group (PcG) proteins, which are crucial epigenetic gene silencers, and found that Id1 regulated the expression of Mel-18 and Bmi-1, both of which belong to PRC1 but not PRC2 complex. We also confirmed that Id1 induced Mel-18 downregulation which was mediated by the Akt pathway, and consequently upregulated the transcription of its target gene c-Myc. Using a promoter-reporter, we demonstrated that Id1 regulated Bmi-1 transcription through c-Myc binding to its E-box in the promoter. Finally, we examined the activity of E3 ligase RING1b whose catalytic activity is increased by binding with the RING finger protein Bmi-1, and found that Id1 over-expression enhanced RING1b E3 ligase activity leading to accumulation of H2A ubiquitination and ubiquitin/proteasome-mediated degradation of Geminin. Taken together, our study provided a novel link between Id1 and PcG proteins and suggested that Id1 may contribute to tumor development through PcG-mediated epigenetic regulation. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr LB-96.
A guidewire-assisted biopsy technique to assist advancement through a biliary stricture to perform selective mapping biopsy
Authors: Hiroshi Kawakami, Masaki Kuwatani, Yoko Abe, Shuhei Kawahata, Kazumichi Kawakubo, Kimitoshi Kubo, Naoya Sakamoto
Journal: Endoscopy (2015)

An endoscopic transpapillary mapping biopsy is useful for evaluating intraepithelial tumor spread in bile duct cancers [1] [2]; however, it is occasionally technically difficult to advance the biopsy forceps through a biliary stricture. Here, we describe the case of a patient with a hilar biliary stricture who underwent a selective mapping biopsy. The biopsy technique described is suitable where the bile duct is inaccessible when introducing conventional biopsy forceps.
SP0136 Genomic Responses in Mouse Models Poorly Mimic Human Inflammatory Diseases
Authors: R.G. Tompkins
Journal: Annals of the Rheumatic Diseases (2014)

<h3></h3> A cornerstone of modern biomedical research is the use of mouse models to explore basic pathophysiological mechanisms, evaluate new therapeutic approaches, and make go or no-go decisions to carry new drug candidates forward into clinical trials. Systematic studies evaluating how well murine models mimic human inflammatory diseases are nonexistent. Our results demonstrate a lack of correlation between human inflammatory diseases and the mouse models used ultimately to create drugs to treat these diseases. Although acute inflammatory stresses from different etiologies result in highly similar genomic responses in humans, the responses in corresponding mouse models correlate poorly with the human conditions and also, one another. Among genes changed significantly in humans, the murine orthologs are close to random in matching their human counterparts (e.g., R<sup>2</sup> between 0.0 and 0.1). Our article provides data for what most investigators already know from their experiences – current mouse models poorly reflect human inflammatory diseases. We do not damn all mouse models. Rather, we propose that the scientific community raise the bar to require model systems to more accurately reproduce the molecular features of human inflammatory disease. In addition to improvements in the current animal model systems, our study supports higher priority for translational medical research to focus on the more complex human conditions rather than relying on mouse models to study human inflammatory diseases. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.1698
Abstract 3462: PARP inhibition sensitizes high grade childhood brain tumors to radiation
Authors: Dannis G. van Vuurden, Olga L.M. Meijer, Esther Hulleman, Thomas Würdinger, David P. Noske, Gertjan L. Kaspers, Jacqueline Cloos
Journal: Cancer Research (2011)

Abstract Background: Poly ADP-ribose polymerases (PARPs) are proteins involved in single strand break repair. Recently, PARP inhibitors have shown considerable promise in the treatment of several cancers, both in monotherapy as in combination with cytotoxic agents. Synthetic lethal action of PARP inhibitors has been observed in tumors with mutations in genes in double strand break repair pathways. Besides this, PARP inhibition enhances sensitivity of tumor cells to DNA damaging agents, such as chemo- and radiotherapy. Aim of this study is to investigate the expression of PARP1 in normal brain tissues and high grade childhood brain tumors, medulloblastoma, ependymoma and high grade glioma (HGG), and to analyse sensitivity and radiosensitizing properties of PARP inhibitor Olaparib in cell lines of these tumors. Methods: Expression of PARP1 has been determined in medulloblastoma, ependymoma and HGG patient material and normal brain tissues by in silico analysis of PARP1 mRNA expression arrays, Western blot and immunohistochemistry. In addition, we performed clonogenic and viability assays, combining radiation with PARP inhibition in medulloblastoma, ependymoma and HGG cell lines. Results: Increased PARP1 expression was observed in medulloblastoma, ependymoma and HGG, as compared to non-neoplastic brain tissue. Moreover, medulloblastoma gene expression analysis revealed high PARP1 expression to be associated with poor prognosis. Growth inhibition with PARP inhibitor Olaparib resulted in differential sensitivity, with IC50 values ranging from 1.8 to 30 µM in cell lines, irrespective of PARP1 protein expression. HGG cell line SF-188, which harbors a focal deletion of NF1 gene, showed a 15-fold higher sensitivity to Olaparib compared to other HGG cell lines. This high sensitivity may be due to synthetic lethality and warrants further investigation. The combination of subcytotoxic concentrations of Olaparib and radiation showed increased cytotoxicity and reduced clonogenic capacity in medulloblastoma, ependymoma and HGG cell lines. Conclusion: PARP1 is overexpressed in high grade childhood brain tumors. In medulloblastoma, high PARP expression is correlated with poor prognosis. PARP inhibition sensitizes ependymoma, medulloblastoma and HGG cells to radiation. These results provide a basis for clinical translation, combining PARP inhibitors with radiotherapy in clinical studies in childhood high grade brain tumors. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 3462. doi:10.1158/1538-7445.AM2011-3462
Dasatinib Plus Capecitabine for Advanced Breast Cancer: Safety and Efficacy Data from Phase 1 Study CA180-004.
Authors: J. Cortes, J. Specht, W. Gradishar, L. Strauss, A. Rybicki, X. Wu, L. Vahdat, L. Paz-Ares, G. Somlo
Journal: Cancer Research (2009)

Abstract Background: SRC is a potential therapeutic target in breast cancer and has a central role in hormone therapy resistance and in osteoclast activity. Dasatinib is a potent SRC inhibitor that inhibits breast cancer cell proliferation and migration in vitro, including synergy with 5FU in some cell lines, and inhibits osteoclast activity in clinical trials. CA180-004 is a phase 1 study designed to identify dose-limiting toxicities (DLT) and recommended phase 2 doses of dasatinib plus capecitabine in women with advanced breast cancer (ABC). Safety and efficacy data are now reported with additional follow-up.Methods: Cohorts of pts with ABC were treated at four dose levels (DL) with capecitabine (mg/m2 twice daily [BID] on D1-14 of 21-day cycles) and dasatinib (mg daily): DL1: capecitabine 825 + dasatinib 50 BID; DL2: capecitabine 825 + dasatinib 70 BID; DL3: capecitabine 1000 + dasatinib 70 BID; DL3a: capecitabine 1000 + dasatinib 100 once daily (QD). All pts had performance status 0-1, prior taxane and/or anthracycline and ≤2 prior chemotherapy-containing regimens for advanced disease. Disease assessments were performed every 6 weeks. DL3a was expanded for further safety and efficacy estimate using best objective response and progression-free survival (PFS) rates.Results: To date, 47 pts with ABC have been treated, 31 in escalation phase plus 16 in expansion (5 too early). Median age was 52 years (range 35-77). Tumor subtypes: 14% were Her2-amplified, 57% ER+ or PR+, 29% triple-negative. Safety was previously reported (ASCO 2009) for escalation phase; no MTD was defined based on DLTs. Of 20 evaluable pts in DL3a, 2 DLTs have been observed: 1 pneumonia, pain and pleural effusion plus 1 diarrhea, neutropenia, vomiting, mucositis and anemia. The most common drug-related adverse events (AEs, any grade) were headache, fatigue/asthenia, nausea/vomiting, diarrhea, hand-foot syndrome (HFS) and pleural effusion. The most common grade 3/4 AEs were fatigue/asthenia, HFS, vomiting and diarrhea. To date, 19 have remained on treatment ≥4 months, including 3 for &amp;gt;1 year. Median duration of treatment (n=42) was 13 weeks; 23 pts have discontinued for progression and 7 for toxicity. Of 38 pts with on-study assessment, 6 had confirmed partial response (treatment durations 17+, 23, 25, 36+, 71, 73 wks), 6 had unconfirmed partial or clinical response (5, 11, 13, 18, 23+, 24 wks), and 9 had prolonged stable disease (16+, 17, 23+, 24+, 25+, 29, 39+, 48+, 63+ wks). Updated efficacy data, including PFS by hormone receptor status, will be presented.Conclusions: Dasatinib and capecitabine combination treatment was well tolerated and encouraging efficacy was observed. Further assessment of this combination is warranted. Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 3092.
Supplemental Perioperative Oxygen to Reduce the Incidence of Surgical-Wound Infection
Authors: Robert Greif, Ozan Akça, Ernst-Peter Horn, Andrea Kurz, Daniel I. Sessler
Journal: New England Journal of Medicine (2000)

Destruction by oxidation, or oxidative killing, is the most important defense against surgical pathogens and depends on the partial pressure of oxygen in contaminated tissue. An easy method of improving oxygen tension in adequately perfused tissue is to increase the concentration of inspired oxygen. We therefore tested the hypothesis that the supplemental administration of oxygen during the perioperative period decreases the incidence of wound infection.
Trends in HIV testing, prevalence among first-time testers, and incidence in most-at-risk populations in Spain: the EPI-VIH Study, 2000 to 2009
Authors: M Diez, M J Bleda, J A Varela, J R Ordoñana, M A Azpiri, M Vall, C Santos, L J Viloria, C de Armas, J  M Ureña, J Trullén, I Pueyo, B Martínez, T Puerta, M Vera, I Sanz, M L Junquera, M C Landa, E Martínez, M M Cámara, J Belda, F  J Bru, A Diaz, Collective for the EPI-VIH Study Group
Journal: Eurosurveillance (2014)

Binary file ES_Abstracts_Final_ECDC.txt matches
I-131 Accumulation in Folliculitis of the Scalp
Authors: SEIGO KINUYA, KUNIHIKO YOKOYAMA, TAKATOSHI MICHIGISHI, NORIHISA TONAMI
Journal: Clinical Nuclear Medicine (1996)

There are numerous conditions known to result in the uptake of radioactive iodine. In a 35-year-old woman, I-131 accumulation was observed in folliculitis of the scalp in the course of I-131 high-dose therapy for follicular thyroid carcinoma. This condition should be added to the list of entities that have extrathyroidal uptake of radioactive iodine, and false-positives results may be caused by small inflammatory lesions.